Over the past week, a few biotech companies made absolutely massive runs. In the past year, the health care sector was on fire from positive trials, U.S. Food and Drug Administration (FDA) approvals, and mergers and acquisitions. These companies that 24/7 Wall St. has picked out kept the fire burning this past week with their huge gains. We have included information about each company, as well as recent trading activity and the consensus price target.

Trevena Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics for G protein-coupled receptors. The company’s central nervous system product pipeline includes TRV130, a small molecule G protein-biased ligand at the mu-opioid receptor, which is in Phase 2 clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred, as well as TRV734, a small molecule G protein-biased ligand at the mu-opioid receptor that is in Phase 1 clinical trials for the treatment of moderate to severe acute and chronic pain. Over the past week, shares were up 76.9%, while year to date they also are up 76.9%. Shares of were trading at $10.76 on Friday’s close. The stock has a consensus analyst price target of $9.75 and a 52-week trading range of $3.80 to $11.94.

ALSO READ: 5 Analyst Stocks With Massive Upside Calls This Week

KaloBios Pharmaceuticals Inc. (NASDAQ: KBIO), a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase 2 clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis, and KB003 that completed a Phase 2 clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. Over the past week, shares were up 100.5%, while year to date they are down 71.3%. Shares of closed most recently at $4.01. The stock has a consensus price target of $5.00 and a 52-week trading range of $1.71 to $17.20.

Synergetics USA Inc. (NASDAQ: SURG) is a medical device company that provides precision surgical devices, surgical equipment and consumables primarily for ophthalmology and neurosurgery markets in the United States and internationally. The company’s product lines focuse on precision engineered disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities, including laser energy, ultrasonic energy, radio frequency energy for electro surgery and lesion generation, and visible light energy for illumination. Over the past week, shares were up 51.2%, while year to date they are up 51.0%. Shares of closed at $6.57. The consensus analyst price target is $6.63. The 52-week trading range is $3.05 to $6.70.

Harvard Apparatus Regenerative Technology Inc. (NASDAQ: HART), a clinical stage biotechnology company, develops and commercializes regenerated organs for human transplant. It is developing the HART-Trachea, which includes a scaffold, the patient’s cells and a bioreactor to restore the structure and/or function of a severely damaged trachea, as well as an automated solid organ bioreactor that has the ability to seed cells on an organ scaffold and keep them sterile and healthy during the growth phase prior to transplant. Over the past week, shares were up 14.0%, while year to date they are down 61.6%. Shares closed at $1.22. The consensus price target is $24.00, and the 52-week range is $0.56 to $8.74.

Champions Oncology Inc. (NASDAQ: CSBR) develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based on the implantation of human tumors in immune-deficient mice. Over the past week, shares were up 3.1%, while year to date they are up 16.6%. Shares were trading at $7.00 on Friday’s close. The 52-week trading range is $2.40 to $10.08.

ALSO READ: 5 Big FDA Decisions Expected in September

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.